$5.53
2.12% yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US0977021049
Symbol
BOLT

Bolt Biotherapeutics Inc Stock price

$5.53
-0.47 7.83% 1M
-4.67 45.78% 6M
-5.17 48.33% YTD
-9.17 62.38% 1Y
-37.87 87.26% 3Y
-637.47 99.14% 5Y
-637.47 99.14% 10Y
-637.47 99.14% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.12 2.12%
ISIN
US0977021049
Symbol
BOLT
Industry

Key metrics

Basic
Market capitalization
$10.6m
Enterprise Value
$-28.2m
Net debt
positive
Cash
$38.8m
Shares outstanding
1.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.9 | 3.0
EV/Sales
negative | negative
EV/FCF
0.5
P/B
0.2
Financial Health
Equity Ratio
57.4%
Return on Equity
-110.4%
ROCE
-87.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.6m | $3.6m
EBITDA
$-61.5m | $-124.7m
EBIT
$-63.3m | $-53.2m
Net Income
$-63.4m | $-46.1m
Free Cash Flow
$-57.9m
Growth (TTM | estimate)
Revenue
-67.8% | -53.1%
EBITDA
15.7% | -87.6%
EBIT
15.5% | 22.1%
Net Income
-0.5% | 27.0%
Free Cash Flow
8.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,691.5% | -3,457.3%
EBIT
-1,738.8%
Net
-1,741.3% | -1,278.1%
Free Cash Flow
-1,591.6%
More
EPS
$-33.0
FCF per Share
$-30.2
Short interest
4.5%
Employees
100
Rev per Employee
$80.0k
Show more

Is Bolt Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Bolt Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Bolt Biotherapeutics Inc forecast:

6x Buy
55%
5x Hold
45%

Analyst Opinions

11 Analysts have issued a Bolt Biotherapeutics Inc forecast:

Buy
55%
Hold
45%

Financial data from Bolt Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.64 3.64
68% 68%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
28% 28%
452%
- Research and Development Expense 50 50
20% 20%
1,386%
-62 -62
16% 16%
-1,691%
- Depreciation and Amortization 1.72 1.72
7% 7%
47%
EBIT (Operating Income) EBIT -63 -63
16% 16%
-1,738%
Net Profit -63 -63
1% 1%
-1,740%

In millions USD.

Don't miss a Thing! We will send you all news about Bolt Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bolt Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
3 months ago
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We continue to make progress advancing our pipeline of first-in-class, novel immunotherapi...
Neutral
GlobeNewsWire
3 months ago
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m.
Neutral
GlobeNewsWire
3 months ago
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for ...
More Bolt Biotherapeutics Inc News

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Head office United States
CEO William Quinn
Employees 100
Founded 2015
Website boltbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today